These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38018663)

  • 1. Unlocking the power of pharmacy services and accelerating access to medications: An update to the impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center.
    Wright BA; Knockel LM
    Pediatr Pulmonol; 2024 Feb; 59(2):526-527. PubMed ID: 38018663
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center.
    Wright BA; Singh SB; Schultz JL; Ramsey LJ; Spading KA; Mascardo LA; Starner TD
    Pediatr Pulmonol; 2019 Oct; 54(10):1591-1595. PubMed ID: 31294925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 5. A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants.
    Wainwright CE
    Am J Respir Crit Care Med; 2022 Nov; 206(10):1193-1195. PubMed ID: 35856818
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing.
    Hoppe JE; Zemanick ET; Martiniano SL
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1308-1310. PubMed ID: 35947636
    [No Abstract]   [Full Text] [Related]  

  • 7. COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No.
    Thursfield RM; Shafi N; Davies JC
    Chest; 2022 Jan; 161(1):21-24. PubMed ID: 35000702
    [No Abstract]   [Full Text] [Related]  

  • 8. A new triple combination cystic fibrosis transmembrane regulator modulator.
    Perrem L; Ratjen F
    Lancet Respir Med; 2023 Jun; 11(6):499-500. PubMed ID: 36842448
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
    Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
    Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming health disparities in access to CFTR modulator therapies: One child's journey with cystic fibrosis.
    Januska MN; Langfelder-Schwind E; Berdella MN
    Pediatr Pulmonol; 2022 Sep; 57(9):2273-2275. PubMed ID: 35637164
    [No Abstract]   [Full Text] [Related]  

  • 11. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.
    Anderson A; McCoy L; Pettit RS; Wright BA; Lubsch L
    Pediatr Pulmonol; 2021 Dec; 56(12):4053-4054. PubMed ID: 34499822
    [No Abstract]   [Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
    Egan ME
    Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIMPLIFYing cystic fibrosis treatment in a post-modulator era.
    Yang C
    Lancet Respir Med; 2023 Apr; 11(4):299-300. PubMed ID: 36463912
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

  • 16. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 17. CFTR Modulator Therapy for Cystic Fibrosis.
    Grasemann H
    N Engl J Med; 2017 Nov; 377(21):2085-2088. PubMed ID: 29099349
    [No Abstract]   [Full Text] [Related]  

  • 18. A multidisciplinary model for prenatal care for patients with cystic fibrosis in the era of highly effective modulator therapy.
    Li SS; Buschur E; Thung SF; Patel AV; Kirkby S
    J Cyst Fibros; 2023 Sep; 22(5):806-810. PubMed ID: 37019745
    [No Abstract]   [Full Text] [Related]  

  • 19. Cystic Fibrosis-Asthma Overlap Syndrome. Combination of Cystic Fibrosis Transmembrane Conductance Regulator Modulators and Type 2 Targeted Biologic Treatment for Asthma.
    Jiménez-Gómez M; Díaz Campos RM; Diab Cáceres L
    Arch Bronconeumol; 2023 Aug; 59(8):512-513. PubMed ID: 37127448
    [No Abstract]   [Full Text] [Related]  

  • 20. Triple CFTR Modulator Therapy for Cystic Fibrosis.
    Holguin F
    N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.